Drugs / KRRO-121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07773246 | Sep 2026 → Aug 2027 expected | arginase deficiency, argininosuccinic aciduria, carbamoyl phosphate synthetase I deficiency disease, citrin deficiency +3 | Korro Bio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-16 | Frequency Therapeutics | Results Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences korrobio.com ↗
KRRO-121, a GalNAc-conjugated oligonucleotide stabilizing Glutamine Synthetase, demonstrates robust ammonia clearance in preclinical hyperammonemia models |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-05 | Frequency Therapeutics | Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 korrobio.com ↗ |
| 2026-04-16 | Frequency Therapeutics | Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences korrobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRRO-121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07773246 ↗ |
| Modality | Oligonucleotide (other) | “GalNAc-conjugated RNA editing oligonucleotide” NCT07773246 ↗ |
| Route | Subcutaneous | “KRRO-121, subcutaneous injection” NCT07773246 ↗ |